Participate in MDMA Studies
We are currently recruiting for the Phase 3 study of MDMA-assisted therapy for PTSD. Here is a list of all MAPS-sponsored trials on clinicaltrials.gov.
Read our Publications
MAPS PBC publishes research papers detailing the results of our clinical trials.
MAPS PBC in the Media
New PTSD Treatments Emerge as Cases Rise Among Some Groups
Sept. 21, 2020
PTSD and psychoactive drugs: MDMA treatment shows potential, but others lack evidence
Sept. 21, 2020
The case for funding psychedelics to treat mental health
Oct 9, 2020
MDMA-assisted couples therapy investigated in landmark pilot trial
December 08, 2020
Press Releases
MAPS-Sponsored Pilot Study: MDMA-Assisted Psychotherapy for PTSD in Couples May Reduce PTSD Symptoms, Improve Couples’ Happiness
Cognitive-behavioral conjoint therapy (CBCT) for posttraumatic stress disorder (PTSD), when combined with MDMA, resulted in significant improvements in PTSD symptoms Six couples, in which one partner was diagnosed with PTSD, participated in a seven-week protocol; both...
Numinus and MAPS Public Benefit Corporation Announce Collaboration Agreement to Seek Approval of MDMA-Assisted Psychotherapy for PTSD Single-Arm, Open-Label Trial
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support...
Study: MDMA-Assisted Psychotherapy May Reduce Anxiety for Those Diagnosed with Life-Threatening Illness
Pilot study explored the application of MDMA-assisted psychotherapy in 18 individuals experiencing moderate to severe anxiety following diagnosis with a life-threatening illness The primary outcome, change in State-Trait Anxiety Inventory (STAI) Trait Scores,...
Study: MDMA-Assisted Psychotherapy Will Be Cost-Effective in the Treatment of PTSD
Healthcare cost savings of MDMA-assisted psychotherapy for PTSD estimated to be greater than $103.2 million with a return of 5,553 Quality of Life Years per 1,000 patients Santa Cruz, CA, October 14, 2020 – A peer-reviewed study published today in the research journal...
MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.